GSK plc (NYSE:GSK) Shares Sold by IHT Wealth Management LLC

IHT Wealth Management LLC decreased its position in shares of GSK plc (NYSE:GSK) by 47.4% in the fourth quarter, HoldingsChannel reports. The firm owned 13,105 shares of the pharmaceutical company’s stock after selling 11,824 shares during the quarter. IHT Wealth Management LLC’s holdings in GSK were worth $443,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of GSK. Stock Yards Bank & Trust Co. acquired a new stake in shares of GSK in the third quarter worth $210,000. World Investment Advisors LLC purchased a new position in shares of GSK during the 3rd quarter valued at about $421,000. Wilmington Savings Fund Society FSB acquired a new position in shares of GSK in the 3rd quarter valued at about $787,000. Optimist Retirement Group LLC boosted its stake in shares of GSK by 3.7% in the third quarter. Optimist Retirement Group LLC now owns 49,554 shares of the pharmaceutical company’s stock worth $2,026,000 after buying an additional 1,790 shares during the last quarter. Finally, Franklin Resources Inc. grew its holdings in GSK by 8.6% during the third quarter. Franklin Resources Inc. now owns 235,348 shares of the pharmaceutical company’s stock worth $9,052,000 after acquiring an additional 18,539 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Trading Down 0.2 %

Shares of NYSE:GSK opened at $37.42 on Friday. The firm has a market capitalization of $77.21 billion, a price-to-earnings ratio of 23.53, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56. The business’s 50 day moving average price is $37.50 and its 200-day moving average price is $36.02. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.93.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. On average, equities research analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, April 10th. Shareholders of record on Friday, February 21st were paid a dividend of $0.3932 per share. This is a positive change from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a yield of 4.20%. The ex-dividend date of this dividend was Friday, February 21st. GSK’s payout ratio is 100.63%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. BNP Paribas started coverage on GSK in a report on Tuesday, April 15th. They issued a “neutral” rating and a $35.25 price target for the company. Morgan Stanley started coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating for the company. Finally, StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Eight investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $40.58.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.